The growing demand for amyloid and tau PET imaging, driven by new dementia therapies and biomarker-based diagnosis, has increased the need for accessible PET brain imaging in outpatient neurology ...

Journal of Nuclear Medicine Technology February 2026, jnmt.125.271835; DOI: https://doi.org/10.2967/jnmt.125.271835 ...

Journal of Nuclear Medicine Technology February 2026, jnmt.125.271428; DOI: https://doi.org/10.2967/jnmt.125.271428 ...

Journal of Nuclear Medicine Technology February 2026, jnmt.125.271265; DOI: https://doi.org/10.2967/jnmt.125.271265 ...

Neurodegenerative diseases are characterized by progressive neuronal dysfunction, synaptic loss, and decline in cognitive, behavioral, or motor function. Understanding these disorders requires a ...

The approval of disease-modifying antiamyloid therapies has expanded the clinical role of amyloid PET beyond diagnostic confirmation to include baseline characterization and longitudinal monitoring of ...

Alzheimer disease (AD) is the most common cause of dementia and one of the leading causes of death in adults age 65 y or older in the United States. AD presents with symptoms of cognitive impairment ...

Neurodegenerative disease profoundly affects structures and pathways responsible for memory, cognition, and higher-order processing. A foundational understanding of neuroanatomy and physiology is ...

Journal of Nuclear Medicine Technology February 2026, jnmt.125.271678; DOI: https://doi.org/10.2967/jnmt.125.271678 Alzheimer disease (AD) is the most common cause of ...

Journal of Nuclear Medicine Technology January 2026, jnmt.125.271203; DOI: https://doi.org/10.2967/jnmt.125.271203 ...

Synthesis of Amyloid Images Using a Generative Adversarial Network from 2-Dimensional 18 F-FDG Images and Evaluation for Clinical Use ...

PET Imaging in Alzheimer Disease in the Era of Antiamyloid Therapy in the United States: Clinical Utility, Quantification, and Policy Landscape ...